Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | LPL | P06858 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267439 | 0.84 | ENPP2 (0.47) | ENPP2TSHRCA2LPLLIPG | |
| SCHEMBL29953195 | 0.84 | ENPP2 (0.47) | ENPP2TSHRCA2LPLLIPG | |
| SCHEMBL16186352 | 0.81 | CA2 (0.47) | ENPP2CA2LPLLIPGCA1 | |
| SCHEMBL15156401 | 0.81 | ENPP2 (0.52) | ENPP2TSHRCA2CA1TTR | |
| SCHEMBL3953042 | 0.78 | TSHR (0.43) | ENPP2TSHRCA2CA1 | |
| SCHEMBL13139989 | 0.78 | ENPP2 (0.48) | ENPP2CA2CA1TTR | |
| SCHEMBL247641 | 0.76 | ENPP2 (0.47) | ENPP2CA2CA1 | |
| SCHEMBL29955494 | 0.76 | ENPP2 (0.47) | ENPP2CA2CA1TTR | |
| SCHEMBL473832 | 0.76 | ENPP2 (0.47) | ENPP2CA2CA1TTR | |
| SCHEMBL28448827 | 0.76 | ENPP2 (0.47) | ENPP2TSHRCA2CA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134116-A1 | CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS | PROTOMER TECHNOLOGIES, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230134116-A1 | CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS | PROTOMER TECHNOLOGIES, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20210369815-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES, INC. | 2021-12-02 | — | — | US | disclosed |
| US-11052133-B2 | Glucose responsive insulins | PROTOMER TECHNOLOGIES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-10941171-B2 | Organometallic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-03-09 | — | — | US | disclosed |
| US-20200399282-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| WO-2019158572-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| US-20190247468-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190153008-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-05-23 | — | — | US | disclosed |
| EP-2417140-A1 | INHIBITORS OF HIV REPLICATION | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115264-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-7799779-B2 | Substituted piperidines as renin inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-1863802-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1987834-A2 | Substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1863802-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103273-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | REN, AGTR1, ACE | ENPP2 2338/4885TSHR 824/4885CA2 465/4885 |
| US-11052133-B2 | Glucose responsive insulins | GLP1R, GPR119, IAPP | ENPP2 282/4885TSHR 76/4885CA2 3108/4885 |
| US-20190247468-A1 | GLUCOSE RESPONSIVE INSULINS | GLP1R, GPR119, IAPP | ENPP2 282/4885TSHR 76/4885CA2 3108/4885 |
| US-20200399282-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC4 | ENPP2 147/4885TSHR 1171/4885CA2 549/4885 |
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | ENPP2 487/4885TSHR 3147/4885CA2 2808/4885 |
| US-20190153008-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, LEF1, POU2F1 | ENPP2 4618/4885TSHR 3162/4885CA2 3952/4885 |
| US-20230134116-A1 | CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS | GPR119, GLP1R, IAPP | ENPP2 995/4885TSHR 631/4885CA2 233/4885 |
| US-20210369815-A1 | GLUCOSE RESPONSIVE INSULINS | GLP1R, GPR119, IAPP | ENPP2 282/4885TSHR 76/4885CA2 3108/4885 |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLR1A, REV1 | ENPP2 3362/4885TSHR 4167/4885CA2 4448/4885 |
| US-10941171-B2 | Organometallic compound and organic light-emitting device including the same | CRY1, LEF1, POU2F1 | ENPP2 4618/4885TSHR 3162/4885CA2 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.